Regenera receives ethics approval for second clinical trial

By Renate Krelle
Wednesday, 20 October, 2004

Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.

Visagen is a preservative free formulation of the steroid triamcinolone acetonide.

The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...

Content from other channels on our network

Beverage facility built to keep the good times rolling

Industries transitioning away from gas, A2EP report released

Six on the shelf: from frozen treats to smoothies & meal kits

58% of food manufacturers report less productivity, research finds

Leadership change at CCEP Australia next year

The roles of the vendor and EPCs in the project bidding process

Seeq and Applied Computing partner on industrial AI for energy operations

ARENA opens Round 3 of Solar Sunshot with $250m available

Testing Profinet I/O devices without a dedicated PLC

CCEP's $39.7m can line upgrade in Perth increases capacity 40%

Industry transitions from gas to renewable heat: report

Boral launches detailed carbon reporting capability

Study assesses recycled content use in home builds

Smart bin receives 2026 Australian Good Design Award

Industrial electricity costs could halve by sharing infrastructure